201 results about "Tartrate" patented technology

The present invention is directed to the tartrate salt of a FAK inhibitor defined by formula I below, and the use of that inhibitor for treating a proliferative disease:

The invention relates to an SNCR (selective non-catalytic reduction) denitration synergist, a denitration composition and a denitration method. The SNCR denitration synergist comprises an organic solvent and alkali metal carboxylate, the mass ratio of the organic solvent to the alkali metal carboxylate is (0.1-1): 1, and the organic solvent is selected from one or more of alcohol, ketone, ether and aldehyde. The alkali metal carboxylate is selected from at least one of formate, acetate, citrate, oxalate, ascorbate and tartrate of alkali metal. According to the SNCR denitration synergist, the denitration efficiency can be remarkably improved in a medium and low temperature interval (600-800 DEG C), ammonia escape is reduced, and secondary pollution is reduced.

The present invention relates to the technical field of the preparation of polyols. Disclosed are a method for preparing a bio-based polyol and a use of the bio-based polyol. In the present invention, a tartrate is selected as a first ring-opening reagent to carry out a first ring-opening reaction on an epoxy group, a second ring-opening reagent containing a secondary alcohol is then used to carry out a second ring-opening reaction, and finally, a primary alcohol is used to carry out a third ring-opening reaction on the rest epoxy group to obtain a bio-based polyol product having an epoxy value close to 0. The bio-based polyol prepared in the present invention is moderate, has a uniform distribution and a relatively low viscosity, and can replace traditional petrochemical polyols. A polyurethane coating prepared from the bio-based polyol prepared by the method of the present invention has remarkably improved performance.

The invention relates to an atherosclerosis animal model feed. The atherosclerosis animal model feed comprises the following raw materials in parts by weight: 20-30 parts of casein, 0.2-0.4 part of sulfur-containing amino acid, 15-25 parts of corn starch, 5-10 parts of maltodextrin, 10-15 parts of fructose, 4-6 parts of cellulose, 15-30 parts of a high-fat substance, 0.2-0.3 part of choline tartrate, 1-2 parts of cholesterol, 3-6 parts of a mineral premix and 0.1-0.2 part of a vitamin premix, the raw material components can be directly mixed, or part of grease is pre-emulsified by adopting vitamin D3, and then the emulsified grease is mixed with other raw materials. According to the invention, the formula components of the feed are optimized, the lard oil and the anhydrous cream are used as high-fat components, and the fructose is used as a main carbon-water source; in addition, the step of adding high-fat substances is optimized, a process of pre-emulsifying part of grease is adopted, an animal model prepared from the feed is closer to the occurrence and development process of human atherosclerosis in the aspects of heredity, lipid metabolism and the like, and the animal model is more suitable for screening drugs for treating atherosclerosis.

The invention relates to application and a method of phosphorus adsorption resin for selectively adsorbing phosphorus from phosphorus-containing wastewater. The phosphorus adsorption resin comprises weak acid cation exchange resin and Fe < 3 + > loaded on the surface of the weak acid cation exchange resin; the pH value of the phosphorus-containing wastewater is 0.8-3.0, the phosphorus concentration is 0.1-5 g / L, and the wastewater further contains 0.1-1 g / L of Ca; the phosphorus adsorption resin is prepared by the following steps: i) carrying out contact reaction on weak acid cation exchange resin and a ferric salt solution, wherein the ferric salt is selected from one or more of ferric sulfate, ferric chloride, ferric nitrate, ferric citrate and ferric tartrate; and ii) after the reaction is completed, carrying out solid-liquid separation to obtain the Fe < 3 + >-loaded phosphorus adsorption resin. According to the method, high-selectivity adsorption (larger than or equal to 95%) of phosphorus can be achieved, the phosphorus and calcium separation effect is good, the iron-calcium ratio in the phosphorus-enriched strip liquor is larger than or equal to 800, and the method can be used for preparing battery-grade iron phosphate.

The invention provides tegorazan D-tartrate and tegorazan phosphate and a preparation method thereof, the tegorazan D-tartrate and the tegorazan phosphate provided by the invention have better dissolving property, meanwhile, the impurity content is slowly increased in a long-term stability test, and excellent water solubility is beneficial to dissolution of a medicine from a pharmaceutical composition, so that the tegorazan D-tartrate and the tegorazan phosphate are suitable for clinical application. The medicine effects including improved bioavailability, maximum blood concentration, peak reaching time and the like can be better exerted. According to the preparation method of the tigorasone new salt, provided by the invention, the use of an organic solvent is reduced, and the problem of organic solvent residue is solved.

A novel salt form of Compound (I) represented by the following structural formula, and its corresponding pharmaceutical compositions, are disclosed.Particular single crystalline forms of 1:1 Compound (I) tartrate salt are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating cancer in a subject.

The invention discloses a tetrahydro-beta-carboline compound as well as a preparation method and application thereof. The tetrahydro-beta-carboline compound is shown as a formula P. The tetrahydro-beta-carboline compound has good RANKL inhibitory activity, the preparation method is simple, raw materials are easy to obtain, and the yield is high. The inhibition activity of the compound on generation of RANKL-induced osteoclasts is determined through a tartrate acid phosphatase (TRAP) staining experiment, it is determined through a surface plasmon resonance (SPR) that the compound has high combining capacity with RANKL protein, and the compound can be used for preparing drugs for preventing and / or treating diseases caused by abnormal osteoclast activity. # imgabs0 #

The present invention discloses a nicotine-tartrate complex, a preparation method and an application, which relate to the technical field of chemical synthesis. The preparation method provided by the present invention includes: Step 1: Completely dissolve tartaric acid in a protic solvent to obtain a tartaric acid solution; Step 2: Dropwise add nicotine to the solution obtained in Step 1, and stir at room temperature until a white solid precipitates. Then, add an aprotic solvent to the reaction system, and the amount of the precipitated solid increases. Continue to stir for 16-24 hours. When the amount of the white solid no longer increases, filter, and wash the filter cake with the aprotic solvent 2-3 times to obtain a white solid; Step 3: Vacuum-dry the white solid obtained in Step 2 to obtain a white solid powder of tartaric acid-nicotine salt complex. This method well solves the problems that the nicotine-tartrate complex is not easy to form a solid and the solid is not easy to dry. The obtained nicotine-tartrate complex solid is a uniform white fluffy powder, which is more convenient to use.

The invention relates to an anti-aging capsule compounded by PQQ and mitochondrial nutrients, and discloses an anti-aging capsule which is prepared by synergistically compounding a plurality of mitochondrial nutrients according to a scientific proportion and supplementing high-purity raw materials and slow-release dosage forms to realize energy metabolism activation and anti-oxidation synergistic intervention. Therefore, the anti-aging capsule systematically delays aging through multi-target regulation and control of mitochondrial functions. The capsule is characterized by comprising the following components in parts by weight: 1-20 mg of pyrroloquinoline quinone disodium salt (PQQ), 20-100 mg of coenzyme Q10, 50-200 mg of L-carnitine tartrate, 10-100 mg of alpha-lipoic acid, 50-300 mg of nicotinamide mononucleotide (NMN) or nicotinamide nucleoside (NR), and 10-50 [mu] g of selenoprotein or organic selenium yeast, and a capsule carrier comprises 100 mg of gelatin or a plant-derived capsule shell, 180 mg of microcrystalline cellulose, 5 mg of magnesium stearate and 5 mg of silicon dioxide.

The present invention is directed to the tartrate salt of a FAK inhibitor defined by formula (I) below, and the use of that inhibitor for treating a proliferative disease.

Sterile filtered liquid lactase composition comprising a lactase, preferably a neutral or acidic lactase, an anion selected from malate, tartrate, citrate, gluconate and / or EDTA and a cation selected from sodium and potassium. Preferably, the composition further comprises a polyol. Addition of the said anions to lactase improves filterability by reducing pressure in a filtration system. Preferably the filtration forms part of an in-line filtration system in the production of a dairy product.

The present invention relates to a compound selected from the group of a lactate salt, a hydrochloride salt, a tartrate salt, a succinate salt, a citrate salt and a maleate salt of the compound of formula (I), (I). The present invention also concerns certain formulations comprising the compound.

The main objective of the present invention is to improve the process for the preparation of ruxolitinib using protected (E)-N-(3-(Dimethylamino)-2-(7H-pyrrolo [2,3-d]pyrimidin-4-yl) allylidene)-N-methylmethanaminium chloride hydrochloride and (R)-5-cyclopentylpyrazolidin-3-one D-tartrate with higher yields on commercial scale. Formula (I):

The present invention belongs to the field of pharmaceutical preparations, and particularly relates to a butorphanol tartrate injection and a preparation method thereof. Each milliliter of the butorphanol tartrate injection comprises: 2 mg of butorphanol tartrate, 0.18 - 2.2 mg of tartaric acid, 2.9 - 3.32 mg of sodium tartrate, 0.01 - 0.5 mg of antioxidant, 6.4 mg of sodium chloride and water for injection, and the pH is 3.0 - 5.0. The butorphanol tartrate injection prepared by the present invention solves the influence of light on the product quality through the synergistic effect of tartaric acid and a specific antioxidant, has good light stability, and at the same time avoids the influence of the leaching of metal ions in the brown glass bottle on the product quality during long-term storage of the product, significantly improves the stability of the product, and thus ensures the effectiveness and safety of the product.

This invention relates to a method for preparing the fenelone intermediate 2-cyanoethyl(4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthidine-3-carboxylic acid ester, and also relates to diastereomeric salts (Va), (Vb), (Vc), and / or (Vd). This method is simple to operate, and the diastereomeric salts can be obtained with very high chemical and enantiomeric purity (tartrate ester content <0.05%) through a single dissociation, avoiding the raw material loss and waste problems caused by multiple dissociations. It also has low production costs and meets the requirements of green production.

This invention discloses a method for resolving isomers of methylfenacin ester, comprising: firstly, dissolving methylfenacin ester in a first solvent and adding L-tartaric acid, dissolving until clear; then adjusting the system temperature to 40℃-53℃ and adding L-tartaric acid seed crystals of the target isomer; subsequently, cooling the system to 20℃-30℃, filtering the precipitated product, and obtaining the L-tartaric acid seed crystals of the target isomer as the filter cake; dissociating the L-tartaric acid seed crystals of the target isomer using an alkaline resin, collecting the filtrate, and drying the filtrate to obtain the target isomer of methylfenacin ester. This invention achieves the resolution of isomers of methylfenacin ester by using L-tartaric acid, and through optimization of conditions, achieves a yield of not less than 74.1% and an ee of 91.1% for the target isomer of methylfenacin ester. The resolution method provided by this invention is simple to operate, easy to control, suitable for large-scale production, and meets industrial needs.

Pharmaceutical compositions comprising tartrate salts of medopredane and methods for making the pharmaceutical compositions are provided. The pharmaceutical composition is useful in the treatment of diseases such as L-DOPA induced dyskinesia.

1. Name of the product under this design: Packaging bag (Tylvalosin tartrate premix). 2. Purpose of the product of this design: used to contain tyvalocin tartrate premix. 3. The key design point of this design product lies in the pattern. 4. The picture or photo that best illustrates the key points of the design: main view. 5. This design product is a flat product, and the left view, right view, top view, bottom view and stereoscopic view are omitted.

The present invention relates to the field of desulfurization technology and proposes a high-efficiency complex iron desulfurizer, its preparation method, and application. The desulfurizer comprises the following components by weight: 25-80 parts of ferric tartrate, 5-20 parts of ferric ethylenediaminetetraacetate, 10-20 parts of an absorbent, 5-20 parts of a stabilizer, 20-30 parts of a synergist, and 500-1000 parts of water. This technical solution solves the problem of low desulfurization efficiency of desulfurizers in related technologies.

The utility model discloses a cold stable filtering equipment for brewing, include: filter jar, the top end of filter jar is used for the hole of external connection pipe, the bottom of hole is fixedly connected with the telescopic pipe for sealing shell, one side of filter jar is provided with the discharge pipe, and one end of discharge pipe extends to the inside of telescopic pipe for sealing shell through the hole, and one end of discharge pipe located telescopic pipe for sealing shell is fixedly connected with the stretch extension pipe. The utility model discloses through drawing out height control mechanism, utilize control electric push rod to push the chain wheel upward, and the chain wheel moves upward and rolls simultaneously, and make its chain located one end of telescopic pipe for sealing shell upward and pull telescopic pipe for sealing shell and stretch extension pipe synchronous rising simultaneously, promote telescopic pipe for sealing shell and stretch extension pipe rising and folding simultaneously, be favorable to according to the wine body flow rate adjustment draw out height, guarantee after the wine liquid of filtering for many times can have enough time to carry out the reprecipitation time again, guarantee the wine body tartrate can remove completely.

The invention discloses a preparation method of high-purity strontium fluoride powder, and relates to the technical field of inorganic material preparation. The method comprises the following steps: crushing and grinding a strontianite block into powder, calcining at high temperature to obtain a first mixture, adding the first mixture into hydrochloric acid, stirring for a certain time, and filtering to remove insoluble substances to obtain first filtrate; regulating and controlling the pH and temperature of the first filtrate, adding tartrate, reacting for a period of time while stirring, and quickly filtering to obtain a second filtrate; adding a fluorine-containing salt solution into the second filtrate at normal temperature, stirring for a period of time, filtering and collecting insoluble substances; and finally, washing the insoluble substance with absolute ethyl alcohol, and carrying out vacuum drying, crushing and grinding to obtain the high-purity strontium fluoride powder. The method is simple and efficient, the purity of the prepared strontium fluoride powder is larger than 99.9%, and the strontium fluoride powder can be used for manufacturing optical glass, advanced electronic elements and the like.

The application discloses an anti-caking salt product and a preparation method thereof. The anti-caking salt product comprises raw salt and an anti-caking agent, the anti-caking agent is food-grade ferric tartrate, and the addition amount of the anti-caking agent is 0.05-0.106 g / kg of the salt. The core of the anti-caking method of the salt lies in that the food-grade ferric tartrate is used as the main anti-caking agent, the addition amount is 0.05-0.106 g / kg of the salt, the salt is dried at 100 DEG C for 4 hours, then the anti-caking agent is added, and the water vapor transmission rate is less than or equal to 0.5 g / m 2 24h of high-barrier material packaging, while 6 g of quicklime or 2 g of calcium chloride desiccant is added in every 200 g of the salt. The application also controls the Mg 2+ content in the salt to be less than or equal to 0.02%, the KCl content to be less than or equal to 10%, and the particle size to be in the range of 0.45-0.6 mm, so that the salt caking is synergistically inhibited from multiple dimensions. The method has extremely significant anti-caking effect (the caking rate is only 8.7% after 15 days of open storage), is safe and economical, and has a simple process, and can effectively replace or reduce the use of potassium ferrocyanide, and is suitable for large-scale industrial production.

This invention relates to an extraction method for improving the bioavailability of tartrate tylosin. The method includes subjecting tartrate fermentation broth to a single acid-dissolution and alkali-precipitation treatment, followed by static crystallization to obtain crude tartrate. This crude tartrate is then subjected to extraction and back-extraction steps, followed by decolorization and ultrafiltration to obtain refined tartrate. Finally, it is spray-dried to obtain tartrate tylosin. This invention optimizes the extraction process of tartrate tylosin by combining a single acid-dissolution and alkali-precipitation crystallization purification process with extraction and back-extraction processes, effectively improving the bioavailability of tartrate tylosin.

The invention provides various salt forms of deuterated dextromethorphan as shown in a formula (I) as well as a preparation method and application of the various salt forms. The various salt forms comprise tartrate, citrate, hydrobromide and benzoate. Also provided are various crystal forms of the above salts. The salt has excellent effects in the aspects of stability, biological activity, bioavailability, drug effect and the like, and is suitable for development of pharmaceutical preparations.

The invention provides an injection capable of treating various cancerous pains and postoperative pains and a preparation method of the injection, and relates to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: filling nitrogen into water for injection at the temperature of 30-60 DEG C, sequentially adding sodium chloride, citric acid and sodium citrate according to a preparation amount, stirring to dissolve the sodium chloride, the citric acid and the sodium citrate, then adding butorphanol tartrate according to a preparation amount, and stirring until the butorphanol tartrate is completely dissolved for later use. According to the preparation method of the butorphinol tartrate injection provided by the invention, the technological parameters are accurately controlled, and the reference preparation prescription of the butorphinol tartrate injection does not need to be changed, so that the sterile guarantee level of the butorphinol tartrate injection can be improved, the increase of the impurity content can be effectively controlled, and the good stability of the butorphinol tartrate injection is ensured.

This invention relates to a method for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthidine-3-carboxylic acid, and also to diastereomeric salts (Va), (Vb), (Vc), and / or (Vd). This method is simple to operate, and the diastereomeric salts can be obtained with very high chemical and enantiomeric purity (tartrate ester content <0.05%) through a single dissociation, avoiding the raw material loss and waste problems caused by multiple dissociations. It also has low production costs and meets the requirements of green production.

Provided herein are crystalline forms of integrin inhibitors, compositions thereof, and methods of their uses. Crystalline forms of tartrate cocrystals of the inhibitors are also described, along with methods of preparing the crystalline forms. X-ray powder diffraction data, thermogravimetric analysis, and differential scanning calorimetry data are provided for the crystalline forms. The integrin inhibitors are useful for treatment of, inter alia, fibrotic diseases.

The present invention relates to a salt form and crystal form of a vaninase inhibitor represented by Formula I, as well as methods for preparing and using the same. The salt form is a salt formed by a compound of Formula I with an acid, and the crystal form is selected from the group consisting of L-tartrate crystal forms A, B, C, and D of the compound of Formula I. The salt of the compound of Formula I of the present invention has high stability and good water solubility, which facilitates enhanced oral absorption and improved bioavailability. The preparation method is simple to operate, easy to control, and highly reproducible, making it suitable for industrial production. The crystal form of the present invention has high stability, good solubility, and low hygroscopicity, and has promising drug development prospects. #imgabs0#

The invention belongs to the technical field of nicotine salt, and relates to 6-methylnicotine-tartrate, a single crystal and a preparation method of the 6-methylnicotine-tartrate. The preparation method of the 6-methylnicotine-tartrate comprises the following steps: S11, dissolving L-tartaric acid in ethanol to obtain an L-tartaric acid solution; s12, dropwise adding 6-methylnicotine into the L-tartaric acid solution to obtain a reaction solution, adding the reaction solution into ethyl acetate, stirring, filtering and washing to obtain a reaction product; and S13, drying the reaction product, so as to obtain the 6-methyl nicotine-tartrate. The technical scheme provided by the invention is simple and easy to operate, low in production cost and high in product purity, can reduce the probability of toxic solvent residues in 6-methylnicotine-tartrate, and is suitable for industrial large-scale production.